Frequently Asked Questions about ProQR Therapeutics N.V. (PRQR)

Name: ProQR Therapeutics N.V. (PRQR) Institutional Financial Dataset
Creator: Olyth
License: https://olyth.xyz

Question 1

What does ProQR Therapeutics N.V. (PRQR) do?

Accepted Answer

ProQR Therapeutics N.V., a biopharmaceutical company, engages in the discovery and development of RNA-based therapeutics for the treatment of genetic disorders. It primarily develops sepofarsen that is in phase II/III clinical trial illuminate trial for treating leber congenital amaurosis 10 disease...

Question 2

Is ProQR Therapeutics N.V. (PRQR) a good stock to buy?

Accepted Answer

Olyth's institutional analysis of PRQR reveals an Altman Z-Score of -4.52 and a Piotroski F-Score of 0/9. These metrics, combined with its 5-year revenue trend ($0.02B most recent), help investors decide if PRQR fits their risk profile.

Question 3

What is the current P/E ratio for PRQR?

Accepted Answer

As of the latest trading session, ProQR Therapeutics N.V. (PRQR) has a trailing P/E ratio of -4.01.

Question 4

Who is the CEO of ProQR Therapeutics N.V.?

Accepted Answer

The current Chief Executive Officer of ProQR Therapeutics N.V. is Daniel Anton de Boer.

Question 5

What was PRQR's revenue for the last 5 years?

Accepted Answer

According to its latest income statements, ProQR Therapeutics N.V. reported annual revenues of $0.02B (2025), $0.02B (2024), $0.01B (2023), $0.00B (2022), $0.00B (2021) respectively.

Question 6

Does PRQR pay a dividend?

Accepted Answer

ProQR Therapeutics N.V. does not currently pay a dividend to its shareholders.

Question 7

How much debt and cash flow does PRQR have?

Accepted Answer

In its latest reporting period, ProQR Therapeutics N.V. generated $-0.05B in Free Cash Flow against a total debt load of $0.01B.

Question 8

What is the Price-to-Book (P/B) ratio of ProQR Therapeutics N.V.?

Accepted Answer

The Price-to-Book (P/B) ratio for ProQR Therapeutics N.V. (PRQR) is currently 3.42.

Question 9

What is the Price-to-Sales (P/S) ratio of PRQR?

Accepted Answer

Based on trailing twelve-month data, ProQR Therapeutics N.V. (PRQR) trades at a Price-to-Sales (P/S) ratio of 10.87.

Question 10

What is ProQR Therapeutics N.V.'s Return on Equity (ROE)?

Accepted Answer

ProQR Therapeutics N.V. (PRQR) has a Return on Equity (ROE) of -65.10%, representing its profitability relative to shareholder equity.